Expert Insights: Treatment Selection in Second-Line R/R CLL and Limitations of Applying MAIC Data in the Real-World Practice Setting

Panelists discuss how second-line treatment selection in relapsed/refractory chronic lymphocytic leukemia (R/R CLL) requires careful consideration of prior therapy exposure, with noncovalent Bruton tyrosine kinase (BTK) inhibitors showing particular promise for patients with BTK resistance mutations while noting that matching-adjusted indirect comparisons (MAIC) analyses, though informative, must be interpreted cautiously in the absence of direct comparative trials.